海特生物(300683) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was CNY 159,406,578.99, a decrease of 4.45% compared to the same period last year, while year-to-date revenue increased by 39.32% to CNY 546,638,804.47[4] - The net profit attributable to shareholders for Q3 2022 was CNY -50,074.74, representing a decline of 100.44% year-on-year, while year-to-date net profit increased by 1.00% to CNY 18,821,966.80[4] - The company reported a 39.32% increase in year-to-date revenue, attributed to the growth in raw materials and intermediates business[8] - The company's revenue from sales of goods and services increased by 35.51% to CNY 493,216,569.03 compared to the same period last year[9] - Total operating revenue for the period reached CNY 546,638,804.47, an increase of 39.3% compared to CNY 392,370,845.33 in the previous period[19] - The net profit for Q3 2022 was CNY 24,700,043, an increase from CNY 19,059,198 in Q3 2021, representing a growth of approximately 29%[21] - Operating profit for Q3 2022 reached CNY 21,733,340, compared to CNY 12,749,034 in the same period last year, indicating a year-over-year increase of about 70%[21] - The total profit for Q3 2022 was CNY 21,168,292.62, an increase from CNY 12,393,017.36 in Q3 2021, reflecting a growth of approximately 71%[21] Cash Flow and Liquidity - The cash flow from operating activities showed a significant increase of 1,321.14% year-to-date, amounting to CNY 5,587,061.30[4] - Cash flow from operating activities generated a net amount of CNY 5,587,061, a significant increase from CNY 393,140 in Q3 2021[25] - The cash received from tax refunds surged by 3512.18% to CNY 15,464,851.54, mainly due to the receipt of tax refunds for retained taxes[9] - Cash flow from investment income increased by 59.57% to CNY 13,478,718.71, driven by higher returns from financial investments[9] - Investment activities generated a net cash flow of CNY 157,463,422, a turnaround from a negative cash flow of CNY -328,566,910 in the previous year[25] - The company’s cash and cash equivalents increased by 84.40% during the reporting period, reflecting improved liquidity[8] - The company reported a total cash and cash equivalents balance of CNY 339,383,162.56 at the end of Q3 2022, down from CNY 769,348,785.27 at the end of Q3 2021[25] Assets and Liabilities - The company's total assets at the end of Q3 2022 were CNY 2,675,416,767.73, a decrease of 0.82% from the end of the previous year[4] - Total assets decreased slightly to CNY 2,675,416,767.73 from CNY 2,697,511,886.43 at the start of the year, a decline of 0.8%[18] - The company's total current assets were CNY 1,432,881,677.64, down 9.4% from CNY 1,582,520,230.13 at the beginning of the year[17] - Total liabilities decreased to CNY 307,661,410.67 from CNY 354,456,572.37, a reduction of 13.2%[18] - The company's total equity rose to CNY 2,367,755,357.06 from CNY 2,343,055,314.06, an increase of 1.1%[18] Research and Development - The company’s R&D expenditure increased significantly by 1,631.37% to CNY 3,178,800.00, indicating a focus on new product development[8] - Research and development expenses increased to CNY 85,474,972.58, reflecting a rise of 17.2% from CNY 72,931,039.37 year-over-year[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,762, with the largest shareholder holding 32.76% of the shares[11] - The company plans to issue up to 36,631,249 shares through a simplified procedure to raise no more than CNY 300 million, which will not exceed 20% of the net assets from the previous year[14] Other Financial Metrics - The company's basic and diluted earnings per share for Q3 2022 were both CNY -0.0004, a decline of 100.37% year-on-year[4] - Investment income decreased by 47.12% to CNY 5,368,756.52, primarily due to the divestiture of subsidiaries in the previous reporting period[9] - The income tax expense decreased by 47.02% to CNY -3,531,750.38, reflecting the growth in profits during the reporting period[9] - The company’s financial expenses decreased to CNY -8,832,983.66 from CNY -9,133,424.13 in the previous year[21] - Basic and diluted earnings per share for Q3 2022 were both CNY 0.15, compared to CNY 0.18 in Q3 2021[22]